Table 2.
Comparison of the Results of Biomarkers between Cases and Controls in Recent Studies.
| Year | First author | Materials | Biomarkers | Case (number) | Control (number) | Data in case | Data in control | p-value | Results | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2019 | Xu C | plasma or serum | 10 miRNAs | 68 OPLL | 45 disc herniation, 53 none myelopathy | ||||
| miR-10a-3p | Increase | |||||||||
| miR-10a-5p | Increase | |||||||||
| miR-563 | Increase | |||||||||
| miR-210-3p | Increase | |||||||||
| miR218-3p | Increase | |||||||||
| miR-196b-5p | Decrease | |||||||||
| miR-129-3p | Decrease | |||||||||
| miR-199b-5p | Decrease | |||||||||
| miR212-3p | Decrease | |||||||||
| miR-218-3p | Decrease | |||||||||
| 2 | 2020 | Ohshima Y | blood | HbA1C>6.5%-no. (%) | 120 OPLL | 1669 none OPLL | 24 (20%) | 185 (11%) | 0.003 | higher incodence |
| TG>150mg/dL-no. (%) | 35 (29%) | 348 (21%) | 0.03 | higher incodence | ||||||
| UA>7.0mg/dL-no. (%) | 25 (21%) | 278 (17%) | 0.239 | NS | ||||||
| 3 | 2019 | Wang P | plasma | IL 17RC, rs199772854C/A | 72 T-OPLL | <0.001 | IL17RC was higher in A than C polymorphism | |||
| 4 | 2018 | Tsuru M | serum | chemokine (C-X-C motif) ligand 7 (CXCL7) | 13 OPLL | 7 healthy control | <0.05 | Decrease | ||
| 5 | 2007 | Eun JP | serum (proteomics) | 9 spots | 6 OPLL | 6 normal subjects | change in ratio | |||
| PRO2675 | 2.81±0.40 | Increase | ||||||||
| Human serum albumin in a complex with myristic acid and tri-iodobenzoic acid | 3.98±0.65 | Increase | ||||||||
| Unknown (protein for IMAGE: 3934797) | 2.55±0.38 | Increase | ||||||||
| Chain B, crystal structure of deoxy-human hemoglobin beta6 | 9.12±0.95 | Increase | ||||||||
| Pro-apolipoprotein | 7.66±0.87 | Increase | ||||||||
| ALB protein | 4.79±0.68 | Increase | ||||||||
| Retinol binding protein | 3.10±0.56 | Increase | ||||||||
| Chain A, human serum albumin mutant R218h complexed with thyroxine (3,3,5,5, tetraiodo-L-thyronine) | 2.36±0.33 | Increase | ||||||||
| 1-microglobulin/bikunin precursor | 0.19±0.15 | Decrease | ||||||||
| 6 | 2020 | Li J | serum(metabolomics and transcriptomics) | uric acid | 25 T-OLF | 23 healthy volunteers | Increase | |||
| triacetin | Increase | |||||||||
| hypoxanthine | Increase | |||||||||
| pyrimidine metabolism | Increase | |||||||||
| purine metabolism | Increase | |||||||||
| 7 | 2014 | Oh YM | PLL tisuue | 25 proteins, Upregulated | 12 OPLL | 12 none OPLL | ||||
| Chain A, Thiredoxin peroxidase B | Upregulated | |||||||||
| Immunogloblin kappa right chainVLJ region | Upregulated | |||||||||
| Ig kappa chain NIG26 Precursor | Upregulated | |||||||||
| Drug-protein interaction: structure of sulfonamide drug complexed with human carbonic anhydrase I | Upregulated | |||||||||
| Hypothetical protein | Upregulated | |||||||||
| 4 proteins, Downregulated | ||||||||||
| Apolipoprotein A | Downregulated | |||||||||
| Proapolipoprotein | Downregulated | |||||||||
| 8 | 2015 | Zhang Y | PLL tissue(proteomic profiling+mRNA expression) | 3 proteins, up-rehulated by proteomic profiling and 1 marker confirmed by mRNA expressuion | 4 OPLL | 4 none OPLL | ||||
| N-RAP | Upregulated | |||||||||
| 18 proteins, down regulated by proteomic profiling and 2 markers confirmed by mRNA expressuion | ||||||||||
| NSDHL | Downregulated | |||||||||
| Viα1 | Downregulated |
PLL: posterior longitudinal ligament HbA1C: glycated hemoglobin OPLL: ossification of the posterior longitudinal ligament NS: not significant
TG: triglycerides OLF: ossification of the ligamentum flavum
UA: uric acid T-OPLL: thoracic OPLL
IL17RC: interleukin-17 receptor C T-OLF: thoracic OLF
N-RAP: nebulin-related anchoring protein
NSDHL: NAD (P) dependent steroid dehydrogenase-like
VIα1: collagen VI alpha-1